Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML - PubMed (original) (raw)

. 2010 Mar 25;115(12):2372-9.

doi: 10.1182/blood-2009-09-241075. Epub 2010 Jan 7.

Todd A Alonzo, Robert B Gerbing, Phoenix A Ho, Rong Zeng, Yaddanapudi Ravindranath, Gary Dahl, Norman J Lacayo, David Becton, Myron Chang, Howard J Weinstein, Betsy Hirsch, Susana C Raimondi, Nyla A Heerema, William G Woods, Beverly J Lange, Craig Hurwitz, Robert J Arceci, Jerald P Radich, Irwin D Bernstein, Michael C Heinrich, Soheil Meshinchi

Affiliations

Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML

Jessica A Pollard et al. Blood. 2010.

Abstract

KIT receptor tyrosine kinase mutations are implicated as a prognostic factor in adults with core binding factor (CBF) acute myeloid leukemia (AML). However, their prevalence and prognostic significance in pediatric CBF AML is not well established. We performed KIT mutational analysis (exon 8 and exon 17) on diagnostic specimens from 203 pediatric patients with CBF AML enrolled on 4 pediatric AML protocols. KIT mutations were detected in 38 (19%) of 203 (95% CI, 14%-25%) patient samples of which 20 (52.5%) of 38 (95% CI, 36%-69%) involved exon 8, 17 (45%) of 38 (95% CI, 29%-62%) involved exon 17, and 1 (2.5%; 95% CI, 0%-14%) involved both locations. Patients with KIT mutations had a 5-year event-free survival of 55% (+/- 17%) compared with 59% (+/- 9%) for patients with wild-type KIT (P = .86). Rates of complete remission, overall survival, disease-free survival, or relapse were not significantly different for patients with or without KIT mutations. Location of the KIT mutation and analysis by cytogenetic subtype [t(8;21) vs inv(16)] also lacked prognostic significance. Our study shows that KIT mutations lack prognostic significance in a large series of pediatric patients with CBF AML. This finding, which differs from adult series and a previously published pediatric study, may reflect variations in therapeutic approaches and/or biologic heterogeneity within CBF AML. Two of 4 studies included in this analysis are registered at http://clinicaltrials.gov as NCT00002798 (CCG-2961) and NCT00070174 (COG AAML03P1).

PubMed Disclaimer

Figures

Figure 1

Figure 1

OS for patients with CBF AML with KIT mutations or WT KIT.

Figure 2

Figure 2

DFS and RR rates for patients with CBF AML with KIT mutations or WT KIT.

Similar articles

Cited by

References

    1. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1, 612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92(7):2322–2333. - PubMed
    1. Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. 2006;24(24):3904–3911. - PubMed
    1. Hann IM, Webb DK, Gibson BE, Harrison CJ. MRC trials in childhood acute myeloid leukaemia. Ann Hematol. 2004;83(Suppl 1):S108–S112. - PubMed
    1. d'Auriol L, Mattei MG, Andre C, Galibert F. Localization of the human c-kit protooncogene on the q11-q12 region of chromosome 4. Hum Genet. 1988;78(4):374–376. - PubMed
    1. Renneville A, Roumier C, Biggio V, et al. Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia. 2008;22(5):915–931. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources